SG11201702177VA - Anti-il-7r antibody compositions - Google Patents
Anti-il-7r antibody compositionsInfo
- Publication number
- SG11201702177VA SG11201702177VA SG11201702177VA SG11201702177VA SG11201702177VA SG 11201702177V A SG11201702177V A SG 11201702177VA SG 11201702177V A SG11201702177V A SG 11201702177VA SG 11201702177V A SG11201702177V A SG 11201702177VA SG 11201702177V A SG11201702177V A SG 11201702177VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody compositions
- antibody
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065612P | 2014-10-18 | 2014-10-18 | |
| PCT/IB2015/057636 WO2016059512A1 (en) | 2014-10-18 | 2015-10-06 | Anti-il-7r antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702177VA true SG11201702177VA (en) | 2017-04-27 |
Family
ID=54337834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702177VA SG11201702177VA (en) | 2014-10-18 | 2015-10-06 | Anti-il-7r antibody compositions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170247460A1 (en) |
| EP (1) | EP3207061A1 (en) |
| JP (1) | JP2016104715A (en) |
| KR (1) | KR20170065662A (en) |
| CN (1) | CN107073113A (en) |
| AU (1) | AU2015332151A1 (en) |
| BR (1) | BR112017007393A2 (en) |
| CA (1) | CA2909491A1 (en) |
| IL (1) | IL251282A0 (en) |
| MX (1) | MX2017004975A (en) |
| RU (1) | RU2017111228A (en) |
| SG (1) | SG11201702177VA (en) |
| WO (1) | WO2016059512A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45488A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| TWI761453B (en) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | Anti-rsv monoclonal antibody formulation |
| CA3054386A1 (en) * | 2017-03-01 | 2018-09-07 | Medimmune Limited | Formulations of monoclonal antibodies |
| JP2020529394A (en) * | 2017-06-16 | 2020-10-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Compositions and Methods for Treating Tauopathy |
| CA3127236A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| MA55033A (en) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | THERAPEUTIC ANTIBODY FORMULATION |
| US11135208B2 (en) * | 2019-08-12 | 2021-10-05 | American Regent, Inc. | 1,4-dihydropyridine compositions, methods of making and use |
| MX2023006596A (en) * | 2020-12-03 | 2023-06-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anti-tslp antibody pharmaceutical composition and use thereof. |
| WO2023245048A1 (en) * | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| KR101222450B1 (en) * | 1999-03-25 | 2013-01-16 | 애보트 게엠베하 운트 콤파니 카게 | Human antibodies that bind human IL-12 and methods for producing |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU1344102A (en) * | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| BRPI0403964B8 (en) * | 2003-04-04 | 2021-05-25 | Genentech Inc | stable liquid formulations, article of manufacture and use of these formulations for the treatment of ige-mediated dysfunction |
| KR20080025174A (en) * | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | Antibody formulations having optimized aggregation and fragmentation profiles |
| CN103977404A (en) * | 2007-06-14 | 2014-08-13 | 比奥根艾迪克Ma公司 | Antibody formulations |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (en) * | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| TWI505838B (en) * | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody |
| WO2011094259A2 (en) | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
| SA114360064B1 (en) | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | Antagonist anti-il-7 receptor antibodies and methods |
| MX2012009755A (en) * | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Stable antibody containing compositions. |
| WO2011109365A2 (en) * | 2010-03-01 | 2011-09-09 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2727602A1 (en) * | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
-
2015
- 2015-10-06 RU RU2017111228A patent/RU2017111228A/en not_active Application Discontinuation
- 2015-10-06 EP EP15784161.0A patent/EP3207061A1/en not_active Withdrawn
- 2015-10-06 US US15/519,803 patent/US20170247460A1/en not_active Abandoned
- 2015-10-06 KR KR1020177013051A patent/KR20170065662A/en not_active Application Discontinuation
- 2015-10-06 AU AU2015332151A patent/AU2015332151A1/en not_active Abandoned
- 2015-10-06 CN CN201580055768.1A patent/CN107073113A/en active Pending
- 2015-10-06 MX MX2017004975A patent/MX2017004975A/en unknown
- 2015-10-06 SG SG11201702177VA patent/SG11201702177VA/en unknown
- 2015-10-06 WO PCT/IB2015/057636 patent/WO2016059512A1/en active Application Filing
- 2015-10-06 BR BR112017007393A patent/BR112017007393A2/en not_active Application Discontinuation
- 2015-10-15 JP JP2015203367A patent/JP2016104715A/en active Pending
- 2015-10-15 CA CA2909491A patent/CA2909491A1/en not_active Abandoned
-
2017
- 2017-03-20 IL IL251282A patent/IL251282A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL251282A0 (en) | 2017-05-29 |
| AU2015332151A1 (en) | 2017-04-27 |
| CA2909491A1 (en) | 2016-04-18 |
| JP2016104715A (en) | 2016-06-09 |
| CN107073113A (en) | 2017-08-18 |
| RU2017111228A3 (en) | 2018-11-21 |
| WO2016059512A1 (en) | 2016-04-21 |
| BR112017007393A2 (en) | 2017-12-19 |
| EP3207061A1 (en) | 2017-08-23 |
| KR20170065662A (en) | 2017-06-13 |
| MX2017004975A (en) | 2017-06-30 |
| RU2017111228A (en) | 2018-11-21 |
| US20170247460A1 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252004B (en) | Domain-exchanged antibody | |
| IL251282A0 (en) | Anti-il-7r antibody compositions | |
| ZA201701461B (en) | Antibody formulations | |
| IL291164A (en) | Anti-nme antibody | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| GB201410520D0 (en) | Antibody | |
| HUE054148T2 (en) | Anti-orai1 antibody | |
| PL3628731T3 (en) | Novel anti-presepsin antibody | |
| IL251479B (en) | Compositions | |
| GB201408167D0 (en) | Compositions | |
| GB201420306D0 (en) | Compositions | |
| GB201419849D0 (en) | Compositions | |
| GB201415526D0 (en) | Antibody Formulations | |
| GB201418776D0 (en) | Antibody | |
| GB201415298D0 (en) | Antibody Formulations | |
| GB201413745D0 (en) | Antibody | |
| GB201411319D0 (en) | Antibody | |
| GB201407535D0 (en) | Antibody Drug - Conjugates |